| TA62 |
Breast cancer - capecitabine (TA62) (replaced by CG81) |
|
-
-
Guidance on the use of capecitabine for the treatment of locally advanced or metastatic breast cancer
This guidance has been replaced by CG81 Breast cancer (advanced)
-
Other information
How this guidance was produced
Background information
- Review decision
- Review proposal
- Media briefing - capecitabine for locally advanced and metastatic breast cancer
- NICE extends range of advice for people with cancer
- A rapid and systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda®) for locally advanced and/or metastatic breast cancer
This page was last updated: 20 December 2011
-
-
Guidance formats
-
Patient
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
NICE Guidance
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
Full Guidance
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.
